Navigating Mental Health Treatment: The Role of Genetic Testing in Medication Management
In recent years, the conversation surrounding mental health has evolved significantly, underscoring the complexities involved in treatment modalities and patient experiences. A poignant example is the story of Lisa Roberts, whose life was abruptly altered by the chronic illnesses of her family members and the untimely death of her mother. Struggling with feelings of despair and emotional numbness, Roberts found herself facing a profound internal conflict—wondering why she was not grieving in the same way as those around her, while simultaneously feeling detached from her daily life and career.
Roberts’s journey led her to consult with Whitnee Brown, a psychiatric nurse practitioner based in Birmingham, Alabama. Recognizing the need for comprehensive support, Brown employed therapeutic exercises to help Roberts process her grief. However, both acknowledged that additional intervention was necessary, prompting a discussion about medication treatment. With a nationwide survey from Myriad Genetics revealing that 89% of Americans diagnosed with depression or anxiety perceive mental health medications as effective, Roberts’s hesitation was notably shared by many. More than half of individuals who have never tried medication expressed reluctance due to potential side effects.
The GeneSight® Mental Health Monitor survey indicates that 54% of patients believe that genetic testing for mental health medications can alleviate concerns about side effects. In this context, Whitnee Brown recommended the GeneSight test to Roberts. This pharmacogenomic tool analyzes genetic variations that could influence patient responses to over 60 commonly prescribed medications for treating conditions such as depression, anxiety, and Attention-Deficit/Hyperactivity Disorder (ADHD).
Pharmacogenomic testing provides essential insights to healthcare providers, allowing them to personalize medication plans based on genetic predilections. Such testing could illuminate whether specific medications may pose a higher risk for side effects, if dosage adjustments are necessary, or if certain options are less likely to yield therapeutic benefits for a patient’s unique genetic profile. Dr. Brown noted that incorporating the GeneSight test into her practice enabled her to navigate the often challenging landscape of medication management with greater confidence.
Following her treatment plan, Roberts experienced a transformative shift—returning not only to her job but also to a renewed sense of purpose and connection with her family. “I am proud to say I just got promoted!” she remarked, reflecting her regained motivation and engagement with life.
For individuals grappling with mental health challenges, particularly those dissatisfied with their current medication regimens, genetic testing might present a viable route to improved treatment outcomes. Those considering this innovative approach are encouraged to connect with healthcare providers to explore whether genetic testing could enhance their mental health treatment options.
To learn more about pharmacogenomic testing and how it could inform your treatment journey, visit GeneSight.com.
Note: The GeneSight Mental Health Monitor survey was conducted by ACUPOLL Precision Research, Inc., which included responses from a representative sample of U.S. adults aged 18 years and older between January 24 and February 10, 2025. The study utilized established mental health screening instruments to ensure thorough analysis.
